All Episodes
TMO EPM / Hemato H9J — 71 episodes
71 - Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
70 - Intermediate-Dose Cytarabine as Postinduction AML Therapy
69 - Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation
61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study
57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults
56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML
43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)
41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease
40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial
31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial
30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE)
29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT
28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up
22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention
21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML
15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation
14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)
10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis
08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients
06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3
04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3
03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia